Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 301–400 of 1,025
van Asten, F., Michels, C. T. J., Hoyng, C. B., van der Wilt, G. J., Klevering, B. J., Rovers, M. M., & Grutters, J. P. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197670 · Cited by 119
Kuroda, Y., Yamashiro, K., Miyake, M., Yoshikawa, M., Nakanishi, H., Oishi, A., Tamura, H., Ooto, S., Tsujikawa, A., & Yoshimura, N. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.053 · Cited by 124
Gomi, F., Oshima, Y., Mori, R., Kano, M., Saito, M., Yamashita, A., Iwata, E., & Maruko, R. (2015) · Retina · doi:10.1097/iae.0000000000000526 · Cited by 119
Kim, S. J., & Toma, H. S. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.213 · Cited by 118
Cheung, C. M. G., & Wong, T. Y. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12227 · Cited by 116
Cerebrovascular Accidents in Ranibizumab
Ueta, T., Yanagi, Y., Tamaki, Y., & Yamaguchi, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.046 · Cited by 117
Wykoff, C. C., Brown, D. M., Reed, K., Berliner, A. J., Gerstenblith, A. T., Breazna, A., Abraham, P., Fein, J. G., Chu, K. W., Clark, W. L., et al. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2023.2421 · Cited by 133
Self-citationYin, V. T., Weisbrod, D. J., Eng, K. T., Schwartz, C. E., Kohly, R. P., Mandelcorn, E. D., Lam, W., Daneman, N., Simor, A. E., & Kertes, P. J. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2379 · Cited by 119
Rasmussen, A., Bloch, S. B., Fuchs, J., Hansen, L. H., Larsen, M., LaCour, M., Lund-Andersen, H., & Sander, B. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.05.018 · Cited by 116
Nutritional supplements for age-related macular degeneration
Krishnadev, N., Meleth, A. D., & Chew, E. Y. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32833866ee · Cited by 116
Campochiaro, P. A., Hafiz, G., Mir, T. A., Scott, A. W., Solomon, S. D., Zimmer-Galler, I. E., Sodhi, A., Duh, E. J., Ying, H. S.-C., Wenick, A. S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.006 · Cited by 117
Ciulla, T. A., Huang, F., Westby, K., Williams, D. F., Zaveri, S., & Patel, S. C. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.01.006 · Cited by 115
Cursiefen, C., Viaud, E., Bock, F., Geudelin, B., Ferry, A., Kadlecová, P., Lévy, M., Mahmood, S. A., Colin, S., Thorin, É., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.03.038 · Cited by 116
Combination therapy for the treatment of ocular neovascularization
Bradley, J. M. B., Ju, M., & Robinson, G. S. (2007) · Angiogenesis · doi:10.1007/s10456-007-9069-x · Cited by 122
“Vision loss was less than 15 letters of visual acuity and one-third of patients (34–40%) gained more than 15 letters of visual acuity, an effect that was sustained over the course of treatment (1–2 years) [24, 25].”
BackgroundInnovative therapies for neovascular age-related macular degeneration
Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1636031 · Cited by 114
“study demonstrated superiority of anti-VEGF-A injections over photodynamic therapy for preserving and recovering VA [86].”
BackgroundGharbiya, M., Allievi, F., Mazzeo, L., & Gabrieli, C. B. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.07.022 · Cited by 114
Trophic factors in the pathogenesis and therapy for retinal degenerative diseases
Kolomeyer, A. M., & Zarbin, M. A. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.09.004 · Cited by 130
Rayess, N., Houston, S. K. S., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.011 · Cited by 117
Orr, P. R., Rentz, A. M., Margolis, M. K., Revicki, D. A., Dolan, C., Colman, S. S., Fine, J. T., & Bressler, N. M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5645 · Cited by 116
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
VANDER, J. F. (2007) · Yearbook of Ophthalmology · doi:10.1016/s0084-392x(08)70110-2 · Cited by 114
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
Dröge, K., Muether, P. S., Hermann, M. M., Caramoy, A., Viebahn, U., Kirchhof, B., & Fauser, S. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2177-3 · Cited by 116
“For neovascular AMD, studies have demonstrated the efficacy of ranibizumab therapy (Novartis, Basel, Switzerland), and have shown significant improvements in visual acuity, macular thickness, and quality of life [1, 2].”
BackgroundVisual Function Decline Resulting from Geographic Atrophy
Heier, J. S., Pieramici, D., Chakravarthy, U., Patel, S. S., Gupta, S., Lotery, A., Lad, E. M., Silverman, D., Henry, E. C., Anderesi, M., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.01.019 · Cited by 111
Self-citationChang, W., Garg, S. J., Maturi, R. K., Hsu, J., Sivalingam, A., Gupta, S. A., Regillo, C. D., & Ho, A. C. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.02.007 · Cited by 117
Digoxin inhibits retinal ischemia‐induced HIF‐1α expression and ocular neovascularization
Yoshida, T., Zhang, H., Iwase, T., Shen, J., Semenza, G. L., & Campochiaro, P. A. (2010) · The FASEB Journal · doi:10.1096/fj.09-145664 · Cited by 111
“Rupture of Bruch’s membrane with laser photocoagulation causes choroidal NV, and inhibition of VEGF strongly suppresses NV in this model and in patients with choroidal NV due to AMD (10, 12, 35, 36).”
BackgroundInfluentialChong, E. W.-T., Kreis, A. J., Wong, T. Y., Simpson, J. A., & Guymer, R. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.005 · Cited by 112
Photodynamic therapy: current role in the treatment of chorioretinal conditions
Newman, D. K. (2016) · Eye · doi:10.1038/eye.2015.251 · Cited by 124
Mière, A., Semoun, O., Cohen, S. Y., Ameen, A. E., Srour, M., Jung, C., Oubraham, H., Querques, G., & Souied, E. H. (2015) · Retina · doi:10.1097/iae.0000000000000819 · Cited by 113
“With the advent of anti–vascular endothelial growth factors (anti-VEGF), a substantial regression of CNV has been achieved, with frequent preservation of central vision.(3) However, several studies have shown”
BackgroundYadav, M., Schiavone, N., Guzmán‐Aránguez, A., Giansanti, F., Papucci, L., de Lara, M. J. P., Singh, M., & Kaur, I. P. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00733-4 · Cited by 119
Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema
Spitzer, M. S., Ziemssen, F., Yoeruek, E., Petermeier, K., Aisenbrey, S., & Szurman, P. (2008) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2007.08.021 · Cited by 113
“Over the past few years, anti-VEGF agents such as ranibizumab, pegaptanib, or off-label bevacizumab have revolutionized the treatment of neovascular ARMD and many other neovascular eye diseases in which increased levels of VEGF are known to have a decisive pathogenetic role.(16,22,23) In contrast, VEGF has not been co…”
BackgroundKiss, S., Liu, Y., Brown, J., Holekamp, N., Almony, A., Campbell, J., & Kowalski, J. (2014) · Clinical Ophthalmology · doi:10.2147/opth.s60893 · Cited by 111
Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes
Ahn, S. J., Ahn, J., Park, S., Kim, H., Hwang, D. J., Park, J. H., Park, J. Y., Chung, J. Y., Park, K. H., & Woo, S. J. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13054 · Cited by 110
Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases
Jones, M. K., Lü, B., Girman, S., & Wang, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.004 · Cited by 125
“Other targeted treatments including ranibizumab (Lucentis, Genentech/Novartis) and bevacizumab (Avastin, Genentech), bind all VEGF-A isoforms and have equivalent efficacy in a head-to-head comparison (Brechner et al., 2011; Brown et al., 2006; Martin et al., 2011; Rosenfeld et al., 2006).”
BackgroundIntravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy
di Lauro, R., Ruggiero, P. D., di Lauro, R., di Lauro, M. T., & Romano, M. R. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1303-3 · Cited by 113
Anti-VEGF therapy: comparison of current and future agents
Pieramici, D. J., & Rabena, M. (2008) · Eye · doi:10.1038/eye.2008.88 · Cited by 112
Ranibizumab for the treatment of neovascular age-related macular degeneration: A review
Kourlas, H., & ABRAMS, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.008 · Cited by 117
Waldstein, S. M., Philip, A.-M., Leitner, R., Simader, C., Langs, G., Gerendas, B. S., & Schmidt-Erfurth, U. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.4948 · Cited by 110
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Seah, I. Y. J., Zhao, X., Lin, Q., Liu, Z., Su, S. Z. Z., Yuen, Y. S., Hunziker, W., Gopal, L., Loh, X. J., & Su, X. (2020) · Eye · doi:10.1038/s41433-020-0770-y · Cited by 117
Towards a better understanding of non-exudative choroidal and macular neovascularization
Sacconi, R., Fragiotta, S., Sarraf, D., Sadda, S. R., Freund, K. B., Parravano, M., Corradetti, G., Cabral, D., Capuano, V., Mière, A., et al. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101113 · Cited by 122
Update on depression and age-related macular degeneration
Casten, R. J., & Rovner, B. W. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835f8e55 · Cited by 110
“Patients also improve in vision function and quality of life [13,14].”
BackgroundPhotodynamic therapy for polypoidal choroidal vasculopathy
Nowak-Sliwinska, P. M., van den Bergh, H., Sickenberg, M., & Koh, A. H. C. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.09.003 · Cited by 113
“The clinical results of AMD treatment trials involving PDT alone or in combination with other treatment modalities are described in detail elsewhere [14–24] and are summarized in Table 10.”
Bacterial Dispersal Associated With Speech in the Setting of Intravitreous Injections
Wen, J. C. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.227 · Cited by 108
VEGF and Intraocular Neovascularization: From Discovery to Therapy
Ferrara, N. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.2.10 · Cited by 114
Xu, D. N., Dávila, J. P., Rahimi, M., Rebhun, C. B., Alibhai, A. Y., Waheed, N. K., & Sarraf, D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.005 · Cited by 109
Holz, F. G., Figueroa, M. S., Bandello, F. M., Yang, Y. C., Ohji, M., Dai, H., Wykrota, H., Sharma, S., Dunger‐Baldauf, C., Lacey, S., et al. (2019) · Retina · doi:10.1097/iae.0000000000002670 · Cited by 118
Engelbert, M., Zweifel, S. A., & Freund, K. B. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cbf · Cited by 108
Voleti, V. B., & Hubschman, J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.01.018 · Cited by 122
Jonas, J. B., Bourne, R., White, R. A., Flaxman, S. R., Keeffe, J. E., Leasher, J. L., Naidoo, K. S., Pesudovs, K., Price, H., Wong, T. Y., et al. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.06.012 · Cited by 121
Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ying, G.-S., Kim, B. J., Maguire, M. G., Huang, J., Daniel, E., Jaffe, G. J., Grunwald, J. E., Blinder, K. J., Flaxel, C. J., Rahhal, F., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1019 · Cited by 107
Polat, O., İnan, S., Özcan, S., Doğan, M., Küsbeci, T., Yavaş, G. F., & İnan, Ü. Ü. (2017) · Türk Oftalmoloji Dergisi · doi:10.4274/tjo.28003 · Cited by 106
Protein delivery for retinal diseases: From basic considerations to clinical applications
Sanharawi, M. E., Kowalczuk, L., Touchard, E., Omri, S., de Kozak, Y., & Béhar‐Cohen, F. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.001 · Cited by 116
“…evaluated: an aptamer, pegaptanib (Macugen ; OSI Pharmaceuticals; Gragoudas et al., 2004), and two anti-VEGF rhumAbs, ranibizumab which is a Fab fragment of rhumAb VEGF, (48 kDa, Lucentis , Genentech Inc.; Rosenfeld et al., 2006; Brown et al., 2006) and bevacizumab (Avastin ; Ratner, 2004).”
BackgroundNeumann, P. J., Chambers, J. D., Simon, F. L., & Meckley, L. M. (2011) · Health Affairs · doi:10.1377/hlthaff.2010.1147 · Cited by 107
Olsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106
“In June 2006, intravitreal ranibizumab rapidly become the standard of care for eAMD.(3,4) The off-label use of bevacizumab, originally introduced systemically,(5,6) has been widely adopted as an intravitreal injection to treat eAMD,(7) largely because it costs less than ranibizumab.”
BackgroundCell-Based Therapy for Degenerative Retinal Disease
Zarbin, M. A. (2019) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-05222-5 · Cited by 106
Revicki, D. A., Rentz, A. M., Harnam, N., Thomas, V. S., & Lanzetta, P. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3766 · Cited by 115
“–21 We evaluated the psychometric characteristics of the NEI VFQ-25 based on pooled data from two ranibizumab clinical trials in patients with AMD.(25,26) The results of this study provide further support for the reliability and validity of the NEI VFQ-25 in patients with AMD.”
BackgroundMethodInfluentialSchmitz-Valckenberg, S., Fleckenstein, M., Göbel, A. P., Hohman, T. C., & Holz, F. G. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5619 · Cited by 112
“Although antibody fragments directed against vascular endothelial growth factor are effective treatments for exudative AMD, GA remains a large, unmet medical need because of its high incidence and the absence of effective treatments.(3,4) Klein et al.”
BackgroundA systematic review on the effect of bevacizumab in exudative age-related macular degeneration
Schouten, J., Heij, E. C. L., Webers, C. A. B., Lundqvist, I. J., & Hendrikse, F. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0952-y · Cited by 108
Ying, G., Maguire, M. G., Daniel, E., Ferris, F. L., Jaffe, G. J., Grunwald, J. E., Toth, C. A., Huang, J., & Martín, D. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.015 · Cited by 112
Scholl, H. P. N., Fleckenstein, M., Fritsche, L. G., Schmitz-Valckenberg, S., Göbel, A., Adrion, C., Herold, C., Keilhauer, C. N., Mackensen, F., Mößner, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007418 · Cited by 104
“To date, successful therapeutic intervention is available only for active CNV, while GA still remains untreatable [8,9].”
BackgroundPegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion
Wroblewski, J. J. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.14 · Cited by 104
Jobling, A. I., Guymer, R. H., Vessey, K. A., Greferath, U., Mills, S. A., Brassington, K. H., Luu, C. D., Aung, K. Z., Trogrlic, L., Plunkett, M. J., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-262444 · Cited by 110
Choi, D. Y., Ortube, M. C., McCannel, C. A., Sarraf, D., Hubschman, J., McCannel, T. A., & Gorin, M. B. (2011) · Retina · doi:10.1097/iae.0b013e318217ffde · Cited by 109
Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., See, R. F., Norton, T., Sánchez, A. I., Risard, S. M., & Avery, R. L. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.021 · Cited by 104
Xu, L., Mrejen, S., Jung, J. J., Gallego-Pinazo, R., Thompson, D., Marsiglia, M., & Freund, K. B. (2015) · Retina · doi:10.1097/iae.0000000000000374 · Cited by 106
“Significant regression of neovascular tissue is rarely observed,(30) and eyes with occult CNV or Type 1 neovascularization in the MARINA study(6) did not gain as many letters of vision when comparing to the eyes with predominantly classic CNV or Type 2 neovascularization in the ANCHOR study.(5) Although this observati…”
MethodResultBloch, S. B., Lund‐Andersen, H., Sander, B., & Larsen, M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.012 · Cited by 108
The Neovascular Age-Related Macular Degeneration Database
Zarranz-Ventura, J., Liew, G., Johnston, R. L., Xing, W., Akerele, T., McKibbin, M., Downey, L., Natha, S., Chakravarthy, U., Bailey, C., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.04.026 · Cited by 103
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
“, 2009 Prospective, open-label, randomized, controlled trial (1-year) 28 PDTþ TC (14) 1.”
Koizumi, H., Kano, M., Yamamoto, A., Saito, M., Maruko, I., Kawasaki, R., Sekiryu, T., Okada, A. A., & Iida, T. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.12.025 · Cited by 106
Holz, F. G., Bandello, F., Gillies, M., Mitchell, P., Osborne, A., Sheidow, T., Souied, E., Figueroa, M. S., & on behalf of the LUMINOUS Steering Committee (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303232 · Cited by 102
de Oliveira Dias, J. R., Rodrigues, E. B., Maia, M., Magalhaes, O., Penha, F. M., & Farah, M. E. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.186361 · Cited by 101
Hata, M., Yamashiro, K., Ooto, S., Oishi, A., Tamura, H., Miyata, M., Ueda‐Arakawa, N., Takahashi, A., Tsujikawa, A., & Yoshimura, N. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20967 · Cited by 103
“This finding supports the speculation that the way in which VEGF is involved in angiogenesis may differ between pachychoroid neovasculopathy and neovascular AMD.”
BackgroundInfluentialAugsburger, M., Sarra, G., & Imesch, P. D. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04404-0 · Cited by 107
AI-based monitoring of retinal fluid in disease activity and under therapy
Schmidt-Erfurth, U. M., Reiter, G. S., Riedl, S., Seeböck, P., Vogl, W., Blodi, B. A., Domalpally, A., Fawzi, A. A., Jia, Y., Sarraf, D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100972 · Cited by 108
Mackensen, F., Heinz, C., Becker, M. D., & Heiligenhaus, A. (2008) · Retina · doi:10.1097/iae.0b013e318156db75 · Cited by 103
Stangos, A. N., Gandhi, J. S., Sahni, J., Heimann, H., Pournaras, C. J., & Harding, S. P. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.05.035 · Cited by 101
Winnik, S. H., Lohmann, C., Siciliani, G., von Lukowicz, T., Kuschnerus, K., Kränkel, N., Brokopp, C. E., Enseleit, F., Michels, S., Ruschitzka, F. T., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.03.010 · Cited by 106
“Pharmacological inhibition of vascular endothelial growth factor (VEGF) improved clinical outcomes in different cancer entities [4–6] and revolutionized the treatment of neovascular age-relatedmacular degeneration (AMD), a leading cause of blindness in the developed world [7–10].”
BackgroundTalks, J. S., Lotery, A. J., Ghanchi, F. D., Sivaprasad, S., Johnston, R. L., Patel, N., McKibbin, M., Bailey, C., Mahmood, S., Lobo, A., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.039 · Cited by 104
Adult Retinal Pigment Epithelial Transplantation in Exudative Age-related Macular Degeneration
Tezel, T. H., Priore, L. V. D., Berger, A. S., & Kaplan, H. J. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.12.007 · Cited by 103
Reducing the Risk of Endophthalmitis Following Intravitreal Injections
Scott, I. U., & Flynn, H. W. (2007) · Retina · doi:10.1097/iae.0b013e3180307271 · Cited by 101
McKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Oishi, A., Tsujikawa, A., Yamashiro, K., Ooto, S., Tamura, H., Nakanishi, H., Ueda‐Arakawa, N., Miyake, M., Akagi-Kurashige, Y., Hata, M., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.018 · Cited by 100
Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ho, A. C., Scott, I. U., Kim, S. J., Brown, G. C., Brown, M. M., Ip, M. S., & Recchia, F. M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.058 · Cited by 100
Surgery for cataracts in people with age-related macular degeneration
Casparis, H., Lindsley, K. B., Kuo, I. C., Sikder, S., & Bressler, N. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006757.pub4 · Cited by 108
Homma, K., Okamoto, S., Mandai, M., Gotoh, N., Rajasimha, H. K., Chang, Y.-S., Chen, S., Li, W., Cogliati, T., Swaroop, A., et al. (2013) · Stem Cells · doi:10.1002/stem.1372 · Cited by 106
Brown, D. M., Heier, J. S., Ciulla, T. A., Benz, M. S., Abraham, P., Yancopoulos, G. D., Stahl, N., Ingerman, A., Vitti, R., Berliner, A. J., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.039 · Cited by 100
Self-citationRothenbuehler, S. P., Waeber, D., Brinkmann, C. K., Wolf, S., & Wolf, S. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.12.005 · Cited by 99
Ting, D. S. W., Ng, W. Y., Ng, S. R., Tan, S. P., Yeo, I. Y. S., Mathur, R., Chan, C. M., Tan, A. C. S., Tan, G. S. W., Wong, T. Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.024 · Cited by 99
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S., Lotery, A. J., Dakin, H. A., Culliford, L., Scott, L. J., Nash, R. L., Taylor, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19780 · Cited by 100
“Outcome Quarter Mean (SE), £ Interaction (95% CI), £ Continuous ranibizumab Discontinuous ranibizumab Continuous bevacizumab Discontinuous bevacizumab Drug cost 1 2189 (15) 2207 (9) 144 (1) 145 (1) –18 (–52 to 17) 2 2113 (23) 953 (69) 137 (2) 78 (5) 1101 (957 to 1245) 3 2097 (27) 1164 (66) 137 (2) 80 (5) 877 (736 to 1…”
BackgroundInflammatory cystoid macular edema
Rothová, A. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f03d2e · Cited by 99
ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA
Cohen, S. Y. (2009) · Retina · doi:10.1097/iae.0b013e3181b1bb1a · Cited by 99
Hoang, Q. V., Tsuang, A. J., Gelman, R., Mendonça, L. S., Torre, K. E. D., Jung, J. J., & Freund, K. B. (2012) · Retina · doi:10.1097/iae.0b013e318261a6f7 · Cited by 101
“Intravitreal ranibizumab (Lucentis; Genentech, San Francisco, CA) and bevacizumab (Avastin; Genentech) are anti–vascular endothelial growth factor (anti-VEGF) agents used to treat choroidal neovascularization and retinal vascular disorders with rarely reported ocular adverse events such as intraocular inflammation, re…”
BackgroundMethod“The patient is speaking”: discovering the patient voice in ophthalmology
Dean, S., Mathers, J. M., Calvert, M., Kyte, D. G., Conroy, D. M., Folkard, A., Southworth, S., Murray, P. I., & Denniston, A. K. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309955 · Cited by 109
Management of neovascular age-related macular degeneration
Schmidt-Erfurth, U. M., & Prünte, C. F. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.03.002 · Cited by 115
Gharbiya, M., Giustolisi, R., Allievi, F., Fantozzi, N., Mazzeo, L., Scavella, V., & Gabrieli, C. B. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.10.010 · Cited by 97
Bakri, S. J., Moshfeghi, D. M., Francom, S., Rundle, A. C., Reshef, D. S., Lee, P. P., Schaeffer, C., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.029 · Cited by 97
Bressler, N. M. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2008.562 · Cited by 96
“The eligibility requirements for patients and eyes, clinical evaluation procedures, and clinical data collection methods and schedules are described in detail elsewhere.(8) Patients were randomized in a 1:1:1 ratio to receive monthly intravitreal injections of 0.”
BackgroundMethodNguyen, Q. D., Shah, S. M., Browning, D. J., Hudson, H. L., Sonkin, P. L., Hariprasad, S. M., Kaiser, P. K., Slakter, J. S., Haller, J. A., & Diana, V. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.030 · Cited by 97
Self-citationBarthelmes, D., Nguyen, V., Daïen, V., Campain, A. E., Walton, R., Guymer, R. H., Morlet, N., Hunyor, A. P., Essex, R. W., Arnold, J., et al. (2017) · Retina · doi:10.1097/iae.0000000000001496 · Cited by 102
Age-Related Macular Degeneration
Khandhadia, S., Cherry, J., & Lotery, A. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0653-2_2 · Cited by 106
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.